Skip to main content

Pomalidomide Dosage

Medically reviewed by Drugs.com. Last updated on Jan 4, 2024.

Applies to the following strengths: 1 mg; 2 mg; 3 mg; 4 mg

Usual Adult Dose for Multiple Myeloma

4 mg orally once a day on Days 1 through 21 of repeated 28-day cycles in combination with dexamethasone until disease progression or unacceptable toxicity

Comments:


Use: In combination with dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy

Usual Adult Dose for Kaposi's Sarcoma

5 mg orally once a day on Days 1 through 21 of repeated 28-day cycles until disease progression or unacceptable toxicity.

Comments:


Uses:

Renal Dose Adjustments

Multiple myeloma (MM) patients with severe renal impairment requiring dialysis: Reduce the dose to 3 mg orally daily.

Kaposi Sarcoma (KS) patients with severe renal impairment requiring dialysis: Reduce the dose to 4 mg orally daily.

Liver Dose Adjustments

DOSE MODIFICATIONS FOR HEPATIC IMPAIRMENT IN PATIENTS WITH MULTIPLE MYELOMA (MM):


DOSE MODIFICATIONS FOR HEPATIC IMPAIRMENT IN PATIENTS WITH KAPOSI SARCOMA (KS):

Dose Adjustments

HEMATOLOGIC DOSE MODIFICATIONS FOR MULTIPLE MYELOMA (MM):
Hematologic adverse reactions: Initiate a new cycle of this drug in patients with multiple myeloma (MM) when the neutrophil count is at least 500/mcL and the platelet count is at least 50,000/mcL.
NEUTROPENIA:

THROMBOCYTOPENIA:

HEMATOLOGIC DOSE MODIFICATIONS FOR KAPOSI SARCOMA (KS):
Hematologic adverse reactions: Initiate a new cycle of this drug in patients with KS when the neutrophil count is at least 1000/mcL and the platelet count is at least 75,000/mcL.
NEUTROPENIA:
FEBRILE NEUTROPENIA:
THROMBOCYTOPENIA:

DOSE MODIFICATIONS FOR NON-HEMATOLOGIC ADVERSE REACTIONS:
the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician's discretion.

DOSE MODIFICATIONS FOR STRONG CYP450 1A2 INHIBITORS:

Precautions

The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for this drug. DRUG and/or SHARED SYSTEM. It includes elements to assure safe use and an implementation system. For additional information: http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm

US BOXED WARNING:


CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

This drug should be taken after completion of dialysis procedure on hemodialysis days.

Other Comments

Administration Advice:


General:

Monitoring:

Patient Advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.